,

Medivas 4

Contains: Pitavastatin Calcium equivalent to Pitavastatin 4 mg
Therapeutic Class: Lipid-Lowering Agent (Statin)
Schedule: Schedule H (Prescription Drug)

Medivas 4 is a lipid-lowering medication used to manage dyslipidemia and reduce the risk of cardiovascular events. It contains Pitavastatin, a potent HMG-CoA reductase inhibitor (statin), which reduces LDL cholesterol, total cholesterol, and triglycerides, while modestly increasing HDL cholesterol.

Unlike other statins, Pitavastatin has a lower potential for drug–drug interactions due to minimal metabolism via the CYP450 system, making it suitable for patients on multiple medications, especially in diabetic, hypertensive, or elderly populations.

Usage of Medivas 4

  • Primary hyperlipidemia and mixed dyslipidemia

  • Familial hypercholesterolemia (heterozygous)

  • Prevention of cardiovascular events in patients with multiple risk factors

  • Suitable for statin-intolerant patients who experienced muscle-related side effects with other statins

  • Can be used in Type 2 diabetic patients for dual benefit on lipid profile and insulin sensitivity


Common Side Effects

  • Headache

  • Myalgia or muscle cramps

  • Back pain

  • Constipation

  • Joint pain

  • Mild elevation in liver enzymes

  • Rare: Rhabdomyolysis (monitor CPK levels if muscle symptoms occur)


Precautions

  • Liver dysfunction: Avoid in active liver disease; monitor LFTs at baseline and periodically

  • Renal impairment: Use with caution in moderate-to-severe renal dysfunction

  • History of muscle disorders: Monitor closely for myopathy or rhabdomyolysis

  • Avoid excess alcohol intake

  • Not recommended in pregnancy or lactation – Category X

  • Discontinue temporarily if the patient develops a serious acute condition (e.g., major surgery, trauma)


Drug Interactions

  • Fewer CYP450 interactions (not significantly metabolized by CYP3A4)

  • Caution with:

    • Fibrates (e.g., gemfibrozil) – ↑ risk of myopathy

    • Cyclosporine – May increase Pitavastatin levels

    • Warfarin – Monitor INR if co-administered

    • Niacin – ↑ risk of liver enzyme elevation and myopathy

  • Safe with many antihypertensives, antidiabetics, and immunosuppressants


Dosage and Administration

  • Once daily, preferably at night (though timing is flexible due to long half-life)

  • Can be taken with or without food

  • Dose adjustment may be needed based on LDL goals, renal function, and tolerance


Storage

  • Store in a cool, dry place below 25°C

  • Protect from light and moisture


Patient Counselling Tips

  • Emphasize the need for long-term adherence even when lipid levels improve

  • Inform about the signs of muscle pain or weakness — report promptly

  • Encourage lifestyle modifications like low-fat diet, regular exercise, and weight management

  • Advise to avoid grapefruit juice (though less likely to interact, still caution is preferred)

  • Do not take during pregnancy or if planning pregnancy

Review My Order

0

Subtotal